Search Result
Results for "
bone formation
" in MedChemExpress (MCE) Product Catalog:
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-15100
-
AAE581
|
Cathepsin
|
Inflammation/Immunology
|
Balicatib (AAE581) is a potent, orally active and selective cathepsin K inhibitor with IC50 values of 22, 61, 48, 2900 nM for cathepsin K, cathepsin B, cathepsin L, cathepsin S, respectively. Balicatib inhibits bone turnover, decreases bone formation rates. Balicatib has the potential for the research of osteoporosis .
|
-
-
- HY-108624
-
|
Others
|
Cardiovascular Disease
Inflammation/Immunology
|
CYM 50769 is a non-peptidic selective antagonist of neuropeptides B and W receptor 1 (NPBWR1). CYM 50769 can attenuates the NPW-23-induced cell proliferation in ATDC5. CYM 50769 can be used for researching endochondral bone formation .
|
-
-
- HY-P0322
-
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
-
- HY-P5929
-
|
Integrin
FAK
|
Inflammation/Immunology
|
VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation .
|
-
-
- HY-P0322A
-
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
-
- HY-150186
-
|
RXFP Receptor
|
Metabolic Disease
|
RXFP2 agonist 2 is a selective,orally active and allosteric RXFP2 agonist with an EC50 value of 0.38 µM. RXFP2 agonist 2 induces osteoblast mineralization. RXFP2 agonist 2 increases bone formation in female mice. RXFP2 agonist 2 has the potential for the research of osteoporosis .
|
-
-
- HY-148043
-
|
Others
|
Others
|
Schnurri-3 inhibitor-1 is a potent schnurri-3 inhibitor which is an essential regulator of adult bone formation. Schnurri-3 inhibitor-1 can inhibit Shn3 with EF1alpha promoter in osteoblast cell line Shn3FFL with an AC50 value of 2.09 μM. Schnurri-3 inhibitor-1 can be used to research osteoporosis .
|
-
-
- HY-116198
-
|
15-PGDH
|
Metabolic Disease
|
15-PGDH-IN-2 (Compound 2) is a 15-PGDH inhibitor with an IC50 value of 0.274 nM. 15-PGDH-IN-2 can be used in research on hair loss, bone formation, gastric ulcer healing, and dermal wound healing .
|
-
-
- HY-127090
-
MDP
|
p38 MAPK
NOD-like Receptor (NLR)
|
Inflammation/Immunology
Cancer
|
Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide is an inducer of bone formation through induction of Runx2. Muramyl dipeptide directly enhances osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide is a NLRP1 agonist .
|
-
-
- HY-128431
-
|
Reactive Oxygen Species
|
Neurological Disease
Metabolic Disease
|
Arochlor 1254 is a polychlorinated biphenyl (PCB) mixture with biphenyl and 54% chlorine. Aroclor 1254 reduced cell viability and induced overproduction of intracellular reactive oxygen species in a dose-dependent manner. Arochlor 1254 exposure reduces calcium homeostasis, osteoblast differentiation and bone formation .
|
-
-
- HY-15147
-
XAV-939
Maximum Cited Publications
115 Publications Verification
|
β-catenin
PARP
|
Cancer
|
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .
|
-
-
- HY-N7702
-
|
Wnt
β-catenin
|
Metabolic Disease
|
N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis .
|
-
-
- HY-P0090
-
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
-
- HY-N10117
-
|
RANKL/RANK
|
Others
|
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
|
-
-
- HY-14839
-
-
-
- HY-148698
-
|
VD/VDR
|
Others
|
2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
|
-
-
- HY-N2403
-
|
Others
|
Neurological Disease
|
Dihydrolycorine, isolated from Lycoris radiate Herb, is an inhibitor of protein synthesis in eukarytic cells by inhibiting the peptide bone formation step .
|
-
-
- HY-17397
-
Distrontium renelate; S12911
|
CaSR
|
Metabolic Disease
|
Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .
|
-
-
- HY-N7646
-
|
Others
|
Others
|
Curculigoside B, a phenolic glycoside isolated from Curculigo orchioides, enhances the osteoblast proliferation, decreases the area of bone resorption pit, osteoclastic formation and TRAP activity. Antiosteoporotic and antioxidative activities .
|
-
-
- HY-11035
-
|
β-catenin
|
Cancer
|
WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor.
|
-
-
- HY-P4823
-
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .
|
-
-
- HY-B1246
-
|
Bacterial
Proton Pump
|
Infection
|
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
|
-
-
- HY-N4299
-
|
Others
|
Metabolic Disease
|
Caesappanin C, a biphenyl dimer from the ethanolic extract of the heartwood of Indonesian Caesalpinia sappan L., shows strong proliferation stimulating activity against the primary osteoblastic cells in vitro. Caesappanin C has the potential to stimulate bone formation and regeneration .
|
-
-
- HY-P4817
-
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis .
|
-
-
- HY-112499
-
Vitamin K2-7; Vitamin K2(35); Vitamin MK-7
|
Others
|
Cardiovascular Disease
|
Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
|
-
-
- HY-149852
-
|
Others
|
Inflammation/Immunology
|
Anti-osteoporosis agent-3 (Compound 11), a PMSA derivative, is an anti-osteoporosis agent. Anti-osteoporosis agent-3 inhibits osteoclastogenesis with an IC50 value of 322.9 nM in vitro. Anti-osteoporosis agent-3 also blocks the formation of F-action belts and bone resorption .
|
-
-
- HY-15106
-
|
CaSR
|
Metabolic Disease
Inflammation/Immunology
|
SB-423557 is an orally active calcium-sensing receptor (CaR) antagonist (IC50=520 nM), precursor of SB-423562 (IC50=73 nM). SB-423557 is well tolerated in human and increases plasma concentrations of exogenous parathyroid hormone (PTH) and stimulates bone formation .
|
-
-
- HY-108742
-
BA 058; BIM 44058
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
|
Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .
|
-
-
- HY-112499R
-
Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)
|
Others
|
Cardiovascular Disease
|
Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
|
-
-
- HY-108742A
-
BA 058 TFA; BIM 44058 TFA
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
Endocrinology
|
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .
|
-
-
- HY-110218
-
|
PKA
Epigenetic Reader Domain
|
Others
|
CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion .
|
-
-
- HY-12398
-
|
VD/VDR
|
Metabolic Disease
Inflammation/Immunology
|
TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
|
-
-
- HY-N6973
-
|
RANKL/RANK
Apoptosis
|
Inflammation/Immunology
|
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK signaling pathway. It can be used in rheumatoid arthritis research .
|
-
-
- HY-130237
-
|
Reactive Oxygen Species
|
Metabolic Disease
Cancer
|
Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .
|
-
-
- HY-110280
-
|
HDAC
Apoptosis
|
Cancer
|
MC1742 is a potent HDAC inhibitor, with IC50s of 0.1 μM, 0.11 μM, 0.02 μM, 0.007 μM, 0.61 μM, 0.04 μM and 0.1 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10 and HDAC11, respectively. MC1742 can increase acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells growth. MC1742 can induce growth arrest, apoptosis, and differentiation in sarcoma CSC .
|
-
-
- HY-N2037A
-
Norcoclaurine hydrochloride
|
MDM-2/p53
ROS Kinase
Apoptosis
|
Infection
Cardiovascular Disease
Endocrinology
Cancer
|
Higenamine hydrochloride is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .
|
-
-
-
HY-L131
-
|
457 compounds
|
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.
Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.
MCE offers a unique collection of 457 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0322
-
EMD 56574
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P0090
-
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
- HY-P4588
-
|
Peptides
|
Metabolic Disease
|
(Glu17,21,24)-Osteocalcin (1-49) (human) is a bone-specific protein involved in bone formation and glucose metabolism .
|
-
- HY-P5929
-
|
Integrin
FAK
|
Inflammation/Immunology
|
VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation .
|
-
- HY-P0322A
-
EMD 56574 TFA
|
Integrin
|
Cardiovascular Disease
Metabolic Disease
|
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
|
-
- HY-P4835
-
|
Peptides
|
Others
|
pTH (2-34) (human) (80 μg/kg) slightly increases serum osteocalcin levels and alkaline phosphatase activity of bone extract (markers of bone formation) in mice. pTH (2-34) is not as effective as pTH (1-34) .
|
-
- HY-P4849
-
|
Peptides
|
Others
|
pTH-Related Protein (1-37) (human, mouse, rat), the peptide analogue of pTH-Related Protein (pTHrP). pTHrP refers to parathyroid-hormone-related protein, involved in physiological regulation of bone formation .
|
-
- HY-P4823
-
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .
|
-
- HY-P4817
-
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis .
|
-
- HY-108742
-
BA 058; BIM 44058
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
|
Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .
|
-
- HY-108742A
-
BA 058 TFA; BIM 44058 TFA
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
Endocrinology
|
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9982
-
|
Inhibitory Antibodies
|
Endocrinology
|
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .
|
-
- HY-P99186
-
|
Inhibitory Antibodies
|
Others
|
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: